Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.97%, which has investors questioning if this is right time to sell.

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

At close: 15 April at 16:00:02 GMT-4 ...

On Wednesday, Truist Securities maintained a Buy rating and a $50.00 price target on Edgewise Therapeutics (NASDAQ:EWTX), ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...